Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
ID: 337917Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)" aimed at encouraging exploratory research projects focused on brain and nervous system disorders, particularly in low- and middle-income countries (LMICs). The initiative seeks to foster innovative collaborations between U.S. scientists and those in LMICs, addressing a wide range of neurological and neurodevelopmental issues, from basic research to implementation strategies, with the goal of building sustainable research capacity and developing effective diagnostics and treatments. Eligible applicants include various institutions such as higher education entities, non-profits, and tribal colleges, with funding of up to $125,000 per year available for a maximum of two years. Interested parties should note that the application deadline is December 9, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional). This funding opportunity encourages exploratory grants for innovative research projects addressing brain and nervous system disorders relevant to low- and middle-income countries (LMICs). The focus includes a wide range of neurological and neurodevelopmental issues, from basic research to implementation strategies. The goal is to foster sustainable research capacity in LMICs, create effective diagnostics and treatments, and develop networking and policy-building initiatives. Key dates include application deadlines in November 2022 and 2023, with an emphasis on collaborations between LMIC and U.S. institutions. Eligible entities include higher education institutions and non-profits, with up to $125,000 available per year for a maximum of two years. This initiative reflects an urgent response to the rising burden of neurological disorders in LMICs, aiming for significant advances in neuro-health research and interventions through collaborative efforts.
    Similar Opportunities
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
    BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity under the BRAIN Initiative for New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21). This initiative invites applications focused on developing innovative technologies to enhance the recording and manipulation of neural activity, particularly at unprecedented scales, while emphasizing the importance of diverse perspectives in the research process. The program aims to advance neuroscience research by addressing critical areas in understanding neural circuits and their functions, with an estimated total program funding of $200,000 and an award ceiling of $200,000 per project. Interested applicants must submit their proposals by June 15, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries," aimed at fostering collaborative research on Alzheimer's disease (AD) and related dementias (ADRD) in low- and middle-income countries (LMICs). This initiative seeks to build sustainable neuroscience research capacity by encouraging partnerships between U.S. researchers and scientists from LMICs, focusing on population-relevant studies that address the unique epidemiological and risk factors associated with AD/ADRD in diverse populations. The program will provide a total of $2.16 million for up to five awards, with individual application budgets capped at $400,000 annually over a five-year period. Interested applicants must submit their proposals by February 14, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)," aimed at supporting research projects that investigate the connections between brain circuit maturation and behavioral development in rodents and non-human primates. The initiative seeks to enhance understanding of how brain region interactions evolve during pre- and postnatal development, particularly in relation to cognitive, affective, and social behaviors, while employing innovative methodologies and in vivo neural measures in awake animals. With a funding ceiling of $275,000 over a two-year period, the application deadline is set for January 7, 2025. Interested applicants can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for clinical studies aimed at advancing next-generation devices for recording and modulation in the human central nervous system, under the BRAIN Initiative. This initiative seeks to support small clinical trials that provide critical data necessary for the development of devices intended to treat central nervous system disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The funding is crucial for enhancing neurotechnology and improving treatment outcomes, with NIH planning to allocate approximately $10 million annually for 5 to 7 awards, each with a maximum budget of $1.5 million per year for up to five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by September 28, 2026.
    BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative for research on the ethical implications of advancements in neurotechnology and brain science, designated as R21 Clinical Trial Optional grants. This initiative invites multi-disciplinary teams to explore critical ethical issues related to brain research, including topics such as brain imaging, data privacy, and informed consent, with the aim of fostering diverse collaborations and addressing significant ethical challenges in the field. The total funding available is $2 million annually over three years, supporting up to eight new awards, with individual project budgets capped at $275,000 for a two-year period. Interested applicants should note that the application period opens on September 11, 2024, and closes on October 9, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 Clinical Trial Not Allowed grant, aimed at advancing research into the cellular and molecular biology of complex brain disorders. This funding opportunity encourages innovative research focused on high-confidence risk factors associated with conditions such as schizophrenia, major depression, and anxiety, emphasizing hypothesis-generating studies rather than disorder modeling. The grant supports projects with budgets up to $275,000 over a two-year period, with applications due starting January 16, 2025, and a closing date of September 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-037.html.